The Company’s BOD resolved to forfeit part of subscription rights of Obigen’s cash capital increase and distribute the rights to its shareholders

1.Date of occurrence of the event:2022/11/24 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable 5.Cause of occurrence:To share the business results of Obigen Pharma Inc. (hereinafter referred to as “Obigen”), the Company’s Board of Directors decide to forfeit part of the preemptive rights of […]

This article is password protected.

To view the content, please enter your password in the field below